| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology, Kitasato University School of Medicine, Kanagawa 228-8555 Japan
Expression of cyclins A and E and cyclin-dependent kinase 2 (CDK2) was examined immunohistochemically in 190 cases of human lung carcinoma. Cyclin A and CDK2 were expressed in the majority of squamous cell carcinomas, small cell carcinomas, and large cell carcinomas, but in significantly fewer cases of adenocarcinomas. Cyclin E was expressed in a minority of all subtypes. In particular, well differentiated cells in squamous cell carcinoma stained positively for cyclin E; in contrast, cyclin A was expressed in the nonkeratinized proliferating areas of the tumor nests. Immunoblotting revealed that all these proteins were expressed at higher levels in tumor tissues than in adjacent normal tissues. Immunoprecipitation also revealed higher levels of cyclin A and cyclin E associated with CDK2 in tumor tissues. Furthermore, tumor tissues which exhibited higher cyclin A and CDK2 expression also had higher CDK2 kinase activity. However, cyclin E-associated kinase activity was barely detectable even in tumor samples exhibiting higher cyclin E expression. Consistent with these data, elevated expression of cyclin A correlated to shorter survival periods in contrast to expression of cyclin E, which correlated to longer survival periods. These results suggest that in human lung carcinomas, elevated expression of active cyclin A-CDK2 complexes with associated higher CDK2 kinase activity is critical for promoting cell cycle progression and unrestrained proliferation of tumor cells and can be a predictive marker for patients' prognosis. On the other hand, immunohistochemical detection of cyclin E-CDK2 reflects accumulation of inactive forms of protein complexes, implying differentiation or senescence of the tumor and the better prognosis.
This article has been cited by other articles:
![]() |
H. Ishibashi, T. Suzuki, S. Suzuki, H. Niikawa, L. Lu, Y. Miki, T. Moriya, S.-i. Hayashi, M. Handa, T. Kondo, et al. Progesterone Receptor in Non-Small Cell Lung Cancer--A Potent Prognostic Factor and Possible Target for Endocrine Therapy Cancer Res., July 15, 2005; 65(14): 6450 - 6458. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, R. Lucas, M. Schuchmann, S. Kuhnle, T. Meergans, A. P. Barreiros, A. W. Lohse, G. Otto, and A. Wendel GM-CSF Restores Innate, But Not Adaptive, Immune Responses in Glucocorticoid-Immunosuppressed Human Blood In Vitro J. Immunol., July 15, 2003; 171(2): 938 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Karan, D. L. Kelly, A. Rizzino, M.-F. Lin, and S. K. Batra Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells Carcinogenesis, June 1, 2002; 23(6): 967 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takano, Y. Kato, P. J. van Diest, M. Masuda, H. Mitomi, and I. Okayasu Cyclin D2 Overexpression and Lack of p27 Correlate Positively and Cyclin E Inversely with a Poor Prognosis in Gastric Cancer Cases Am. J. Pathol., February 1, 2000; 156(2): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shoji, Y. Dobashi, S. Morinaga, S.-X. Jiang, and T. Kameya Tumor Extension and Cell Proliferation in Adenocarcinomas of the Lung Am. J. Pathol., March 1, 1999; 154(3): 909 - 918. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |